These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Time trends in survival from cancer of unknown primary: small steps forward. Riihimäki M; Hemminki A; Sundquist K; Hemminki K Eur J Cancer; 2013 Jul; 49(10):2403-10. PubMed ID: 23518210 [TBL] [Abstract][Full Text] [Related]
23. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Pimiento JM; Teso D; Malkan A; Dudrick SJ; Palesty JA Am J Surg; 2007 Dec; 194(6):833-7; discussion 837-8. PubMed ID: 18005780 [TBL] [Abstract][Full Text] [Related]
25. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096 [TBL] [Abstract][Full Text] [Related]
26. Unknown primary adenocarcinomas: a single-center experience. Uzunoglu S; Erdogan B; Kodaz H; Cinkaya A; Turkmen E; Hacibekiroglu I; Sari A; Ozen A; Usta U; Cicin I Bosn J Basic Med Sci; 2016 Nov; 16(4):292-297. PubMed ID: 27455119 [TBL] [Abstract][Full Text] [Related]
27. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Meier S; Baumert BG; Maier T; Wellis G; Burg G; Seifert B; Dummer R Onkologie; 2004 Apr; 27(2):145-9. PubMed ID: 15138346 [TBL] [Abstract][Full Text] [Related]
28. Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. Hammoud MA; McCutcheon IE; Elsouki R; Schoppa D; Patt YZ Ann Surg Oncol; 1996 Sep; 3(5):453-63. PubMed ID: 8876887 [TBL] [Abstract][Full Text] [Related]
29. Diagnosis and management of carcinoma of unknown primary in the head and neck. Issing WJ; Taleban B; Tauber S Eur Arch Otorhinolaryngol; 2003 Sep; 260(8):436-43. PubMed ID: 12684829 [TBL] [Abstract][Full Text] [Related]
30. The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. Chen J PLoS One; 2018; 13(8):e0200909. PubMed ID: 30102707 [TBL] [Abstract][Full Text] [Related]
31. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Kodaira M; Takahashi S; Yamada S; Ueda K; Mishima Y; Takeuchi K; Yamamoto N; Ishikawa Y; Yokoyama M; Saotome T; Terui Y; Hatake K Ann Oncol; 2010 Jun; 21(6):1163-1167. PubMed ID: 20019088 [TBL] [Abstract][Full Text] [Related]
32. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. Yakushiji S; Ando M; Yonemori K; Kohno T; Shimizu C; Katsumata N; Fujiwara Y Int J Clin Oncol; 2006 Dec; 11(6):421-5. PubMed ID: 17180509 [TBL] [Abstract][Full Text] [Related]
33. Analysis of survival in patients with brain metastases treated surgically: Impact of age, gender, oncologic status, chemotherapy, radiotherapy, number and localization of lesions, and primary cancer site. Rotta JM; Rodrigues DB; Diniz JM; Abreu BM; Kamimura F; Sousa UO; Botelho RV; Oliveira MF Rev Assoc Med Bras (1992); 2018 Aug; 64(8):717-722. PubMed ID: 30673042 [TBL] [Abstract][Full Text] [Related]
34. The assessment of clinicopathological features, therapy pattern and survival benefit of 162 gastric cancers with liver metastases. Li J; Lu M; Li J; Zhang X; Li Y; Zhan X; Shen L Hepatogastroenterology; 2013 May; 60(123):628-32. PubMed ID: 23108083 [TBL] [Abstract][Full Text] [Related]
35. Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years. Thöm I; Rogers C; Andritzky B; Witzel I; Schuch G; Hossfeld DK; Bokemeyer C; Laack E Onkologie; 2009 Dec; 32(12):741-6. PubMed ID: 20016235 [TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients. Budnik J; Suri J; Bates JE; Bylund KC; Milano MT Clin Genitourin Cancer; 2019 Aug; 17(4):260-267. PubMed ID: 31101579 [TBL] [Abstract][Full Text] [Related]
37. Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature. Petrakis D; Pentheroudakis G; Voulgaris E; Pavlidis N Cancer Treat Rev; 2013 Nov; 39(7):701-8. PubMed ID: 23566573 [TBL] [Abstract][Full Text] [Related]
38. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202 [TBL] [Abstract][Full Text] [Related]
39. Management and prognosis of patients with cancer of unknown primary: 20 years of experience. Bardakçi M; Algin E; Düğeroğlu B; Bal Ö; Köş FT; Uncu D Turk J Med Sci; 2023; 53(6):1722-1731. PubMed ID: 38813492 [TBL] [Abstract][Full Text] [Related]
40. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]